Patty said that for caregivers, it’s essential to lean on the care team for information specific to the procedure, medication ...
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...
FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...
BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...
Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the ...
In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...
BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...
Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...
FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results